AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

Huemer, M; Rebhandl, S; Zaborsky, N; Gassner, FJ; Hainzl, S; Weiss, L; Hebenstreit, D; Greil, R; Geisberger, R; Eur J Immunol. 2014; 44(12):3747-3757

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.

Brodowicz, T; Lang, I; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Petruzelka, L; Eniu, A; Anghel, R; Koynov, K; Vrbanec, D; Pienkowski, T; Melichar, B; Spanik, S; Ahlers, S; Messinger, D; Inbar, MJ; Zielinski, C; Br J Cancer. 2014; 111(11): 2051-2057.

Bone-Targeted Therapy in Metastatic Breast Cancer – All Well-Established Knowledge?

Gampenrieder, SP; Rinnerthaler, G; Greil, R BREAST CARE. 2014; 9(5): 323-330.

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.

Te Raa, GD; Malčiková, J; Mraz, M; Trbusek, M; Le Garff-Tavernier, M; Merle-Béral, H; Greil, R; Merkel, O; Pospíšilová, S; Lin, K; Pettitt, AR; Stankovic, T; van Oers, MH; Eldering, E; Stilgenbauer, S; Zenz, T; Kater, AP; Br J Haematol. 2014; 167(4): 565-569.

Quality of care of rural rheumatoid arthritis patients in Austria.

Puchner, R; Brezinschek, HP; Herold, M; Nothnagl, T; Studnicka-Benke, A; Fritz, J; Leeb, BF; Wien Klin Wochenschr. 2014; 126(11-12): 360-367.

Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays – implications for response-guided therapy in genotype 1 infections.

Taylor, N; Haschke-Becher, E; Greil, R; Strasser, M; Oberkofler, H; Antivir Ther. 2014; 19(5): 449-454.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

McGale, P; Taylor, C; Correa, C; Cutter, D; Duane, F; Ewertz, M; Gray, R; Mannu, G; Peto, R; Whelan, T; Wang, Y; Wang, Z; Darby, S; Lancet. 2014; 383(9935): 2127-2135.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb, J; Tabernero, J; Mini, E; Subtil, F; Folprecht, G; Van Laethem, JL; Thaler, J; Bridgewater, J; Petersen, LN; Blons, H; Collette, L; Van Cutsem, E; Rougier, P; Salazar, R; Bedenne, L; Emile, JF; Laurent-Puig, P; Lepage, C; Lancet Oncol. 2014; 15(8): 862-873.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd, JC; Brown, JR; O“Brien, S; Barrientos, JC; Kay, NE; Reddy, NM; Coutre, S; Tam, CS; Mulligan, SP; Jaeger, U; Devereux, S; Barr, PM; Furman, RR; Kipps, TJ; Cymbalista, F; Pocock, C; Thornton, P; Caligaris-Cappio, F; Robak, T; Delgado, J; Schuster, SJ; Montillo, M; Schuh, A; de Vos, S; Gill, D; Bloor, A; Dearden, C; Moreno, C; Jones, JJ; Chu, AD; Fardis, M; McGreivy, J; Clow, F; James, DF; Hillmen, P; N Engl J Med. 2014; 371(3): 213-223.

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.

Geretti, AM; Conibear, T; Hill, A; Johnson, JA; Tambuyzer, L; Thys, K; Vingerhoets, J; Van Delft, Y; J Antimicrob Chemother. 2014; 69(4): 1090-1097.